Andalusian Agency for Health Technology Assessment (AETSA)
|
|
- Baldric Weaver
- 5 years ago
- Views:
Transcription
1 Andalusian Agency for Health Technology Assessment (AETSA) Seville, 22 nd of July, 2016 Comments on the concept paper Facilitating the translation of advanced therapies to patients in Europe 1
2 Introduction AETSA welcomes the publication of this important and well-addressed concept paper on Facilitating the translation of advanced therapies to patients in Europe. Also we would like to thank the IMI for the opportunity to comment. AETSA s comments will reflect the perspective of a regional health technology assessment organisation with HTA activity on pharmaceutical and nonpharmaceutical products. We have also developed intensive collaborative joint work with the Spanish National HTA strategy on both lines (pharma and nonpharmaceuticals 1 ). We understand the need to review and establish specific and adapted HTA processes for ATMPs as they represent a new and innovative health technology type. However, at the same time we would also like to stress the importance of establishing clearly stated and scientific rigorous methods for safety and effectiveness assessment that being known by ATMPs developers could be taken into account in designing clinical trials and also embraced by all HTA organizations. As it is mentioned in the concept paper, ATMPs development is an area of great interest for public health, patients and citizens. In this sense, all participants in defining access to ATMPs have the responsibility to minimize possible risks involved. Furthermore, but not less important, there is a necessity of new models for cost-effectiveness analysis in order to agree prices and reimbursement procedures that make the access to AMTPs sustainable for the public health systems. Below we describe some issues and considerations that we would like to share alongside our experiences. We present them as answers to the proposed questions. AETSA would welcome the opportunity to participate as an 1 The Andalusian Agency for Health Technology Assessment was established by the Government of Andalusia in 1996, as part of a new program to promote the use of costeffectiveness analysis and evidence-based medicine in the regional health service. Since 2012, AETSA is a member of the Spanish HTA Network, a public HTA body that support decision to National Health Service Portfolio. Our main goal is to promote the appropriate use of health technologies (pharmaceuticals and non-pharmaceuticals), providing decision-makers with critically review information about their efficacy, safety, and effectiveness. We also consider the economic, social, ethic and legal impact. We work in coordination with the Spanish HTA Network (for assessment of medical devices and procedures) and the Therapeutic Positioning Report Group in the Spanish Medicine Agency, AEMPS (for pharmaceuticals). Our main products are systematic reviews and cost-analyses reports. We encourage the widespread participation of medical professionals in our assessment projects as part of our strategy to enhance quality of care and efficiency. AETSA also coordinates groups for developing evidence-based clinical guidelines and for developing recommendations about selection and use of new pharmaceuticals and new technologies that are likely to have a major cost or social impact in the Andalusian Public Health System. AETSA is a member of the following international networks: INAHTA, EuroScan, HTAi, and EUnetHTA (foundational member). More information at: We are also in 2
3 interested party in some of the discussions that could take place alongside this paper. Considerations and experiences 1. Have the key challenges that can be addressed through collaborative, public-private initiatives been properly identified? We agree that IMI have identified the key challenges that are critical in facilitating the translation ATMPs to patients. Nevertheless, we consider that there is another important opportunity related to the ATMPs clinical development which has not been outlined i.e. collaboration between ATMPs developers and HTA organizations at the very early stage of Initial Evidence Generation (IEG), the step in the health technology life cycle in which the clinical trials are developed. The collaborative process is considered to be essential in this early stage of IEG, and Early Dialogues (EDs) are the forum that has been designed to fulfil this need. EDs contribute to the development of high quality clinical trials protocols. The data and evidence generated by clinical trials resulting from these EDs process are expected to be adjusted to the requirement of the HTA process and consequently, HTA reports will be better to support the decision making process regarding early access to the ATMPs. EDs will lead to more timely and straightforward assessments, resulting in an appropriate access to, and coverage of, patients needs. The methodology for these EDs have been already established at European level. AETSA has taken part in the project Shaping European Early Dialogues (SEED) funded by the European Commission and coordinated by HAS (France). Also we have participated in the Joint Action 2 on HTA (develop by EUnetHTA collaboration and funded as well by the European Commission) in the specific work package related to EDs. In both projects, process and methods for EDs among technologies developers and HTA organizations have been both specifically designed and piloted. Also we have taken part in designing and piloting experiences about parallel/joint scientific advice with EMA as a part of SEED project. The EDs established process is going to be put in place and consolidated as a real-life exercise during the EUnetHTA Joint Action 3 ( ), through the activities of a specific work package that is going to be dedicated to the life cycle approach to improving the process of Evidence Generation. In general, collaboration among drug companies and all other participants that are involved in the development and access to new drugs is considered to be essential in order to avoid the duplication of work and uncoordinated study requests. As well as enabling the collection of consistent data that can be combined across organisations and countries to support assessments and decision making processes. 3
4 2. Which of the proposed potential initiatives should be prioritised? Although we acknowledge that the development of reimbursement and payment mechanisms should have high priority, we consider that the review of HTA process for ATMPs, discussion among HTA organizations and those and stakeholders should be also prioritised. Developing and/or adapting tools to assess ATMPs should happen along with the development of guidelines that establish the methods to assess the clinical studies (comparator, endpoints, duration of the trials) and with the design of specific ones to demonstrate the long-term efficacy and safety follow-up. 3. Are any areas missing? AETSA would like the following missing issues in the topics indicated for future research investment to be taken into consideration. - Regarding the HTA implications: The necessity and benefits of harmonization in methods for ATMPs HTA assessment among HTA organizations. The benefits of joint health technology assessments among HTA organizations in terms of efficiency in HTA (we would like to highlight again in this point the EUnetHTA Joint Action 3 that is going to continue with the joint work initiated in previous joint actions). It is necessary to take into account and further develop the methodology for indirect comparisons for ATMPs. It is also a requirement to develop and do research on statistical methods to extrapolate, when necessary, the data from the clinical trials to the long term and to elaborate guidance about them. Moreover, it would be necessary to define clear criteria and conditions in which these methods are going to be considered appropriate. We will need tools to evaluate the quality of evidence generated by these methods. In this regards, AETSA understands the need to avoid unnecessary studies at long term but would like to stress the importance of observational prospective studies in the practice of evidence-based medicine in this new field of ATMPs. Working with electronic health records and real-world data could help to answer clinical research questions about ATMPs effectiveness and safety. - Regarding Hospital Exemption (HE): AETSA would remark the importance of observational prospective studies in this field, based on registries as possible, to generate new evidence about effectiveness and safety in cases of HE. 4
5 - Regarding reimbursement and payment mechanisms: there are other issues that could be taken under consideration such as patient access schemes used in special circumstances (i.e. oncology, cancer, etc.) and their adaptation for ATMPs. Based on the experience of orphan drug or end-of-life treatments, criteria for ATMPs reimbursement could be developed. In the same way, the use of risk sharing schemes that require the existence of registries, follow-up, and continuous assessment could be taken into account. On the other hand, generating adequate data for pricing, reimbursement and market access during clinical development is one of the main challenges for manufactures. Therefore, the promotion and use of new models of publicprivate partnership to develop ATMPs and give access to them will bring potential benefits. 4. What are the key European or national initiatives that IMI shall synergise with? - At European level and related with HTA activities: HTA Network and EUnetHTA collaboration. As we have mentioned before, the Joint Action 3 on HTA will have a work package (WP) that is going to be devoted to the life cycle approach to improve Evidence Generation. This WP will support developers of medical technologies (pharmaceuticals, medical devices and diagnostics) by providing a collaborative approach between a wide range of European HTA agencies on their product development plans. By integrating structures that facilitate the exchange of different perspectives, learning, efficiency, and consistency throughout EDs (or scientific advice), they will optimize the interaction with regulators for pharmaceuticals and medical devices. Alongside this, pilots regarding post-launch evidence generation will be conducted. A number of pilots will be using data from registries, others will be using data from sources other than registries. A wide range of stakeholders will be involved in the pilots in order to catch all the relevant aspects. This will lead to the development of a tool to support permanent collaboration on post-launch evidence generation. Thirty-nine organizations (among them AETSA) will participate in this WP. - At national level: Therapeutic position reports initiative that is coordinated by the Spanish Medicine Agency (AEMPS). AETSA collaborates intensively in this initiative. - At a regional level, we would like to remark the following initiative: - Andalusian Initiative for Advanced Therapies, from Andalusia, Spain. ( The Andalusian Initiative for Advanced Therapies is promoted by the Andalusian Government to foster research in the field of advanced therapies to develop safe and efficient treatments to offer to the population. 5
Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA
EUnetHTA European network for Health Technology Assessment Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA University of Tokyo, October 24,
More informationReflection Paper on synergies between regulatory and HTA issues. DG SANTE Unit B4 Medical products: safety, quality, innovation
Reflection Paper on synergies between regulatory and HTA issues DG SANTE Unit B4 Medical products: safety, quality, innovation STAMP meeting, 28 June 2016 Outline Aim of the Reflection Paper Drafting process
More informationEuropean Network for Health Technology Assessment (EUnetHTA) Joint Action 3
European Network for Health Technology Assessment (EUnetHTA) Joint Action 3 Zoe Garrett, Senior Technical Adviser Lead WP7 National Implementation and Impact National Institute for Health and Care Excellence
More informationDecember Eucomed HTA Position Paper UK support from ABHI
December 2008 Eucomed HTA Position Paper UK support from ABHI The Eucomed position paper on Health Technology Assessment presents the views of the Medical Devices Industry of the challenges of performing
More informationHTA Position Paper. The International Network of Agencies for Health Technology Assessment (INAHTA) defines HTA as:
HTA Position Paper The Global Medical Technology Alliance (GMTA) represents medical technology associations whose members supply over 85 percent of the medical devices and diagnostics purchased annually
More informationEU Cooperation on Health Technology Assessment
Strategy for EU Cooperation on Health Technology Assessment Strategy for EU cooperation on Health Technology Assessment (HTA) The HTA Network is a voluntary network, set up by Directive2011/24 (article
More informationMedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017)
MedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017) Table of Contents Executive Summary...3 The need for healthcare reform...4 The medical technology industry
More informationEnpr EMA. Enpr-EMA. European Network of Paediatric Research at the European Medicines Agency
Enpr EMA European Network of Paediatric Research at the European Medicines Agency Enpr-EMA European Network of Paediatric Research at the European Medicines Agency An agency of the European Union Enpr
More informationFinn Børlum Kristensen, MD, PhD Director, EUnetHTA Secretariat Danish Health and Medicines Authority (EUnetHTA Coordinator) Copenhagen, Denmark
EUnetHTA European network for Health Technology Assessment DATABASES, REGISTRIES AND OTHER DATA CAPTURE TOOLS: HOW CAN WE AVOID MULTIPLICITY AND CREATE AN INTEGRATED DATA-CAPTURE APPROACH ALONG THE PRODUCT
More informationHealth Technology Assessment of Medical Devices in Low and Middle Income countries: challenges and opportunities
Health Technology Assessment of Medical Devices in Low and Middle Income countries: challenges and opportunities Aleksandra Torbica, Carlo Federici, Rosanna Tarricone Centre for Research on Health and
More informationReduce cost sharing and fees Include other services. Services: which services are covered? Population: who is covered?
3.3 Assessment: National health technology assessment unit 3.3.1 Introduction Health systems throughout the world are struggling with the challenge of how to manage health care delivery in resource-constrained
More informationEU s Innovative Medical Technology and EMA s Measures
EU s Innovative Medical Technology and EMA s Measures 27 October 2017 Summit symposium 25-27 October 2017, Kyoto, Japan Presented by Guido Rasi Executive Director, European Medicines Agency (EMA) An agency
More informationNew methods, how could Norway speed up Health Technology Assessment (HTA) to the benefit of health industry, policy-makers, clinicians and patients?
New methods, how could Norway speed up Health Technology Assessment (HTA) to the benefit of health industry, policy-makers, clinicians and patients? Department director Øyvind Melien Reviews and HTA, Norwegian
More informationHealth Technology Assessment and the European Network for HTA
Health Technology Assessment and the European Network for HTA www.eunethta.eu Marcial Velasco Garrido, Technische Universität Berlin for the European Network for HTA, EUnetHTA Outline What is Health Technology
More informationSHTG primary submission process
Meeting date: 24 April 2014 Agenda item: 8 Paper number: SHTG 14-16 Title: Purpose: SHTG primary submission process FOR INFORMATION Background The purpose of this paper is to update SHTG members on developments
More information'INNOVATIVE SOLUTIONS FOR RESEARCH IN HEALTHCARE' Developing a novel approach to deliver better precision medicine in Europe The EMA standpoint
'INNOVATIVE SOLUTIONS FOR RESEARCH IN HEALTHCARE' Developing a novel approach to deliver better precision medicine in Europe The EMA standpoint STOA workshop - European Parliament, 10 January 2019 Presented
More informationHTA, the roadmap from investment to disinvestment
HTA, the roadmap from investment to disinvestment Dr. Iñaki Gutiérrez-Ibarluzea Secretary of HTAi Osteba. Osasun Teknologien Ebaluazioaren Zerbitzua. Basque Office for HTA. Osasun Saila Ministry for Health
More informationBiomedical Innovation Has Science Overtaken the System?
Adaptive Pathways for Transformative Medicinal Products. A New Paradigm with the Enhanced Application of Real-World Evidence? ISPOR 20 th Annual European Congress, Glasgow, Scotland Issue Panel 21, Wednesday,
More informationThe EFPIA Perspective on the GDPR. Brendan Barnes, EFPIA 2 nd Nordic Real World Data Conference , Helsinki
The EFPIA Perspective on the GDPR Brendan Barnes, EFPIA 2 nd Nordic Real World Data Conference 26-27.9.2017, Helsinki 1 Key Benefits of Health Data Improved decision-making Patient self-management CPD
More informationA Focus on Health Data Infrastructure, Capacity and Application of Outcomes Data
External Review of Pan-Canadian Health Organizations Thank you for the opportunity to provide input for your ongoing review of the Pan- Canadian Health Organizations (PCHOs). This submission is made on
More informationAdaptation of HTA reports: an effective way to use limited resources?
Adaptation of HTA reports: an effective way to use limited resources? Iñaki Gutiérrez-Ibarluzea, Osteba, Basque Office for HTA. Ministry for Health, Basque Government Introducing the Basque Country Basque
More informationEMA experience with the review of digital technology proposals in medicine development programmes
EMA experience with the review of digital technology proposals in medicine development programmes 3rd Industry Stakeholder Platform on R&D support, 18 May 2018 Francesca Cerreta, Scientific Advice An agency
More informationRegulatory Science For Innovation
Regulatory Science For Innovation Fergal Donnelly European Commission Directorate-General for Research & Innovation Directorate 'Industrial Technologies' Unit 'Advanced Materials and Nanotechnology' The
More informationFinal Minutes of EMA/EUnetHTA meeting
4 June 2013 EMA/297283/2013 14 May 2013 chaired by Hans-Georg Eichler and Finn Børlum Kristensen Role Chairs Participants Name Hans-Georg Eichler and Finn Børlum Kristensen EMA: Peter Arlett, Michael Berntgen,
More informationHealth Technology Assessment: What are the key challenges to assess medical devices? Rosanna Tarricone, PhD Director CERGAS Scientific Director EHTI
Health Technology Assessment: What are the key challenges to assess medical devices? Rosanna Tarricone, PhD Director CERGAS Scientific Director EHTI SAMED, Annual Conference, May 29 th 2014 From «Does
More information25 th Workshop of the EURORDIS Round Table of Companies (ERTC)
25 th Workshop of the EURORDIS Round Table of Companies (ERTC) Healthcare Companies & European Reference Networks: Expectations & Potential for Collaboration Introduction Tuesday 26 September, 2017 (09:00
More informationDraft Plan of Action Chair's Text Status 3 May 2008
Draft Plan of Action Chair's Text Status 3 May 2008 Explanation by the Chair of the Drafting Group on the Plan of Action of the 'Stakeholder' Column in the attached table Discussed Text - White background
More informationIssues in Emerging Health Technologies Bulletin Process
Issues in Emerging Health Technologies Bulletin Process Updated: April 2015 Version 1.0 REVISION HISTORY Periodically, this document will be revised as part of ongoing process improvement activities. The
More informationTable Of Content. Stichting Health Action International... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs...
Table Of Content... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs... 7 D08 - HAI Europe Newsletter (EN)... 7 D01 - HAI Europe leaflet (EN)... 7 D02 - Briefing Papers and statements
More informationHow can value be measured and assessed?
Dávid Dankó, PhD, MSc Corvinus University of Budapest Institute of Management david.danko at uni-corvinus.hu How can value be measured and assessed? ISPOR 5 th Asia-Pacific Conference, Taipei, 2 September
More informationCollaboration at time of market entry (from regulatory opinion to joint REA production)
EMA-EUnetHTA Meeting Minutes 08 June 2017 11:00 to 16:00 CET Meeting Venue: ZIN Offices - Eekholt 4 1112 XH Diemen Role Chairs Present Regrets Name Wim Goettsch and Hans-Georg Eichler EUnetHTA: Chantal
More informationE5 Implementation Working Group Questions & Answers (R1) Current version dated June 2, 2006
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE E5 Implementation Working Group & (R1) Current version dated June 2, 2006 ICH Secretariat,
More informationIV/10. Measures for implementing the Convention on Biological Diversity
IV/10. Measures for implementing the Convention on Biological Diversity A. Incentive measures: consideration of measures for the implementation of Article 11 Reaffirming the importance for the implementation
More informationIP7: CHANGING PARADIGM IN THE EVALUATION OF THE VALUE OF MEDICAL DEVICES: WHAT MUST STAKEHOLDERS EXPECT IN THE NEW DECADE?
IP7: CHANGING PARADIGM IN THE EVALUATION OF THE VALUE OF MEDICAL DEVICES: WHAT MUST STAKEHOLDERS EXPECT IN THE NEW DECADE? Department director Øyvind Melien Assessment interventions, Norwegian Institute
More informationStrategies for Knowledge Translation and Mobilization to Inform Hospital Health Technology Use
Strategies for Knowledge Translation and Mobilization to Inform Hospital Health Technology Use Rosmin Esmail MSc, CHE Director, Knowledge Translation Research, Analytics and Innovation Portfolio Alberta
More informationENCePP Work Plan
EMA/150117/2014 ENCePP Secretariat European Network of Centres for Pharmacoepidemiology and Pharmacovigilance European Network of Centres for Pharmacoepidemiology and Pharmacovigilance Adopted by the ENCePP
More informationHTA in Norway- HTA - international challenges
NVTAG Symposium Drugs: An international perspective HTA in Norway- HTA - international challenges Berit Mørland, President HTAi Deputy director, The Norwegian Knowledge Centre for the Health Services My
More informationThe New Delhi Communiqué
India-EU Ministerial Science Conference 7-8 February 2007, New Delhi The New Delhi Communiqué BACKGROUND TO CONFERENCE At their Summit in Helsinki in October 2006, the leaders of the EU and India reiterated
More informationEUROPE March Brussels, Belgium CALL FOR ABSTRACTS. Join Us at the Crossroads of Healthcare. DIAglobal.org/Europe2020 #DIAEurope2020
EUROPE 2020 17-19 March Brussels, Belgium CALL FOR ABSTRACTS Join Us at the Crossroads of Healthcare I1 Steering Committee Francis Arickx INAMI, Belgium Matthieu Boudes EPF, Belgium Sini Eskola EFPIA,
More informationTranslational scientist competency profile
C-COMEND Competency profile for Translational Scientists C-COMEND is a two-year European training project supported by the Erasmus plus programme, which started on November 1st 2015. The overall objective
More informationPOSITION OF THE NATIONAL RESEARCH COUNCIL OF ITALY (CNR) ON HORIZON 2020
POSITION OF THE NATIONAL RESEARCH COUNCIL OF ITALY (CNR) ON HORIZON 2020 General view CNR- the National Research Council of Italy welcomes the architecture designed by the European Commission for Horizon
More informationdemonstrator approach real market conditions would be useful to provide a unified partner search instrument for the CIP programme
Contribution by the Ministry of Industry and Trade of the Czech Republic to the public consultations on a successor programme to the Competitiveness and Innovation Framework Programme (CIP) 2007-2013 Given
More informationChanging landscape - changing paradigms
IP7: CHANGING PARADIGM IN THE EVALUATION OF THE VALUE OF MEDICAL DEVICES: WHAT MUST STAKEHOLDERS EXPECT IN THE NEW DECADE? Department director Øyvind Melien Assessment interventions, Norwegian Institute
More informationABHI Response to the Kennedy short study on Valuing Innovation
ABHI Response to the Kennedy short study on Valuing Innovation Introduction 1. The Association of British Healthcare Industries (ABHI) is the industry association for the UK medical technology sector.
More informationTWO BY TWO: A METHODOLOGICAL PERSPECTIVE ON THE USE OF EVIDENCE TO SUPPORT THE VALUE OF A HEALTH TECHNOLOGY
TWO BY TWO: A METHODOLOGICAL PERSPECTIVE ON THE USE OF EVIDENCE TO SUPPORT THE VALUE OF A HEALTH TECHNOLOGY A/Prof Tracy Merlin Adelaide Health Technology Assessment (AHTA) School of Population Health
More informationParenteral Nutrition Down Under Inc. (PNDU) Working with Pharmaceutical Companies Policy (Policy)
Parenteral Nutrition Down Under Inc. (PNDU) Working with Pharmaceutical Companies Policy (Policy) BACKGROUND (Reason or Purpose) The purpose of this Policy is to provide clear principles and guidance about
More informationGreen Paper - From Challenges to Opportunities: Towards a Common Strategic Framework. for EU Research and Innovation Funding
Green Paper - From Challenges to Opportunities: Towards a Common Strategic Framework for EU Research and Innovation Funding Position of the European Brain Council (EBC) Introduction The European Brain
More informationResearch Development Request - Profile Template. European Commission
Research Development Request - Profile Template European Commission Research Development Request Profile The following table can be used as a template for drafting a Research Development Request profile.
More informationHorizon Scanning. Why & how to launch it in Lithuania? Prof. Dr. Rafael Popper
VTT TECHNICAL RESEARCH CENTRE OF FINLAND LTD Horizon Scanning Why & how to launch it in Lithuania? Prof. Dr. Rafael Popper Principal Scientist in Business, Innovation and Foresight VTT Technical Research
More informationThe NHS England Assurance Framework: national report for consultation Chief Officer, Barnet Clinical Commissioning Group
Meeting Health and Well-Being Board Date 27 June 2013 Subject Report of Summary of item and decision being sought The NHS England Assurance Framework: national report for consultation Chief Officer, Barnet
More informationHealth Technology Assessment of innovative medical devices
Health Technology Assessment of innovative medical devices Dr. Iñaki Gutiérrez-Ibarluzea Knowledge Manager Vicepresident of EuroScan International Network Osteba, Basque Office for HTA Ministry for Health
More informationCurrent Status and Challenges of Bilateral/Multilateral Meetings
Current Status and Challenges of Bilateral/Multilateral Meetings Junko Sato, PhD International Liaison Officer PMDA 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The views and
More informationMedical Education Activities
Medical Education Activities Author: Marie-Claire PICKAERT EFPIA Deputy Director General BioMed Alliance Brussels, 9 November 2016 MCP 07-11--2016 Declaration of Interest Marie-Claire Pickaert is a full-time
More informationHealth Technology Assessment (HTA) Dr Hamid Ravaghi
Health Technology Assessment (HTA) Dr Hamid Ravaghi Why? What? How? 3 Why? New technologies Cost of new technologies Limited resources Ethical questions WHAT? Health Technology Instruments, equipment,
More information9 Vaccine SMEs' Needs
9 Vaccine SMEs' Needs As in most innovative sectors, SMEs play a critical role in bridging basic discoveries from academic research to clinical development 36. This could be seen over the last decade with
More informationMapping of HTA in Europe " Regulatory and Reimbursement Atlas"
CIRS- Centre for Innovation in Regulatory Science 1 CONSENSUS TRUST ACCESS Mapping of HTA in Europe " Regulatory and Reimbursement Atlas" Tina Wang Manager, HTA Programme twang@cirsci.org 20 May 2016 Brussels,
More informationSMA Europe Code of Practice on Relationships with the Pharmaceutical Industry
Introduction SMA Europe Code of Practice on Relationships with the Pharmaceutical Industry SMA Europe is an umbrella body of national Spinal Muscular Atrophy patient representative and research organisations
More informationHealth & Social Care Industrial Innovation
Health & Social Care Industrial Innovation Mr Andrew Fowlie Scottish Government Health Innovations Team SHINE North Sea Region Program 2014 2020 Scotland s Medical Technologies Landscape Imaging Non Imaging
More informationclarification to bring legal certainty to these issues have been voiced in various position papers and statements.
ESR Statement on the European Commission s proposal for a Regulation on the protection of individuals with regard to the processing of personal data on the free movement of such data (General Data Protection
More informationUsing European Joint HTAs in local settings to adopt or to adapt, that is
Using European Joint HTAs in local settings to adopt or to adapt, that is Katrine Frønsdal, BASc MSc PhD Norwegian Institute of Public Health (NIPH) Third WHO Global Forum on Medical Devices Centre International
More informationCADTH HEALTH TECHNOLOGY MANAGEMENT PROGRAM Horizon Scanning Products and Services Processes
CADTH HEALTH TECHNOLOGY MANAGEMENT PROGRAM Horizon Scanning Products and Services Processes Service Line: Health Technology Management Program Version: 1.0 Publication Date: September 2017 Report Length:
More informationWebinar IMI2 - Call 15 Digital endpoints in neurodegenerative and immunemediated
Webinar IMI2 - Call 15 Digital endpoints in neurodegenerative and immunemediated diseases 18.07.2018 Agenda How to use GoToWebinar Catherine Brett, IMI Introduction Colm Carroll, IMI The Call topic Vaibhav
More informationEU Research Integrity Initiative
EU Research Integrity Initiative PROMOTING RESEARCH INTEGRITY IS A WIN-WIN POLICY Adherence to the highest level of integrity is in the interest of all the key actors of the research and innovation system:
More informationTOWARD TRANSPARENCY IN HEALTH TECHNOLOGY ASSESSMENT
International Journal of Technology Assessment in Health Care, 19:1 (2003), 1 7. Copyright c 2003 Cambridge University Press. Printed in the U.S.A. TOWARD TRANSPARENCY IN HEALTH TECHNOLOGY ASSESSMENT A
More informationInnovation in HTA: What is the additional value?
Innovation in HTA: What is the additional value? Stirling Bryan Centre for Clinical Epidemiology & Evaluation, Vancouver Coastal Health Research Institute School of Population & Public Health, UBC My co-authors
More informationIMI Revolutionising Europe s Pharmaceutical Industry. IMI Matters!
IMI Revolutionising Europe s Pharmaceutical Industry IMI Matters! Session in the Framework of the Event Joint Technology Initiatives Innovation in Action 4 6 October 2011 European Parliament Brussels Programme
More informationTool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases
Tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases In 2017 the multi-stakeholder initiative was set up to: Facilitate a shared understanding of the
More informationIMI2 Intellectual Property rules in light of Call 10 topics. Magali Poinot, IMI Legal Manager IMI Stakeholder Forum 28 September 2016
IMI2 Intellectual Property rules in light of Call 10 topics Magali Poinot, IMI Legal Manager IMI Stakeholder Forum 28 September 2016 One policy for multiple interests Support to industry Incentive to participate
More informationPOWERED BY SCRIP SPONSORED BY
GETTING IT RIGHT Drawing Together Key Stakeholders To Shape The Real-World Data Revolution POWERED BY SCRIP SPONSORED BY 1 February 2019 During an expert panel convened by PAREXEL and Pharma Intelligence
More informationENCePP Work Plan
EMA/231507/2012 ENCePP Secretariat European Network of Centres for Pharmacoepidemiology and Pharmacovigilance European Network of Centres for Pharmacoepidemiology and Pharmacovigilance Adopted by the ENCePP
More informationOverview of Health Technology Assessment (HTA) from Asia Pacific Perspective
Overview of Health Technology Assessment (HTA) from Asia Pacific Perspective Hong Li, PhD., MPH Group Director, Bristol-Myers Squibb Adjunct Associate Professor University of Cincinnati, USA; and DUKE-NUS
More informationNCRIS Capability 5.7: Population Health and Clinical Data Linkage
NCRIS Capability 5.7: Population Health and Clinical Data Linkage National Collaborative Research Infrastructure Strategy Issues Paper July 2007 Issues Paper Version 1: Population Health and Clinical Data
More informationWHO Workshop, Bangkok, Health Technology Assessment
WHO Workshop, Bangkok, 11.09.2010 Health Technology Assessment 1. Introduction to Health Technology Assessment (HTA) Berit Mørland, Norway 2. HTA & Government Keng Ho PWEE, Singapore 3. HTA and Clinical
More informationEngaging UK Climate Service Providers a series of workshops in November 2014
Engaging UK Climate Service Providers a series of workshops in November 2014 Belfast, London, Edinburgh and Cardiff Four workshops were held during November 2014 to engage organisations (providers, purveyors
More informationIntegrated Scientific Advice Workshop: ISPOR Glasgow
Integrated Scientific Advice Workshop: ISPOR Glasgow Early Integrated Scientific Advice in Product Development: Get Real and Adapt to Accelerate Patient Access ICONplc.com Overview At today s patient-centered
More information28 March Report of the Working Group on Pharmaceuticals and Public Health of the High Level Committee on Health.
PHARMACEUTICALS AND PUBLIC HEALTH IN THE EU: PROPOSALS TO THE HIGH LEVEL COMMITTEE ON HEALTH FOR POLICIES AND ACTIONS IN THE FRAMEWORK OF THE TREATY OF AMSTERDAM a) 28 March 2000 a) Report of the Working
More informationStanding Committee on the Law of Patents
E SCP/24/4 ORIGINAL: ENGLISH DATE: JUNE 29, 2016 Standing Committee on the Law of Patents Twenty-Fourth Session Geneva, June 27 to 30, 2016 PROPOSAL BY THE AFRICAN GROUP FOR A WIPO WORK PROGRAM ON PATENTS
More informationInter-Association Task Force
Inter-Association Task Force Presentation to EMA Workshop Prevention of Drug Shortages Based on Quality and Manufacturing Issues 9 th October 2015 1 Topics for Today Background and history of task force
More informationEDQM COUNCIL OF EUROPE CONFERENCE CERTIFICATION PROCEDURE : 20 YEARS OF EXPERIENCE March EDQM, Strasbourg, France ABSTRACTS
EDQM COUNCIL OF EUROPE CONFERENCE CERTIFICATION PROCEDURE 1992-2012: 20 YEARS OF EXPERIENCE 22-23 March 2012 EDQM, Strasbourg, France ABSTRACTS PLENARY SESSION, 22 March 2012 ABSTRACT 1.3 The Evolution
More informationNanomaterials: Applications, Implications and Safety Management in the SAICM Context Rob Visser
Nanomaterials: Applications, Implications and Safety Management in the SAICM Context Rob Visser The Regulatory Challenge of Nanotechnology 20 January 2012 Bern, Switzerland 1 SAICM context: ICCM 2 considered
More informationCREDITING-RELATED READINESS ACTIVITIES UNDER THE PMR: UPDATE AND SUGGESTED NEXT STEPS
CREDITING-RELATED READINESS ACTIVITIES UNDER THE PMR: UPDATE AND SUGGESTED NEXT STEPS PMR Note PA12 2015-1 May 15, 2015 1 I. INTRODUCTION 1. The Partnership for Market Readiness (PMR) was established in
More informationA New Platform for escience and data research into the European Ecosystem.
Digital Agenda A New Platform for escience and data research into the European Ecosystem. Iconference Wim Jansen einfrastructure DG CONNECT European Commission The 'ecosystem': some facts 1. einfrastructure
More informationWG/STAIR. Knut Blind, STAIR Chairman
WG/STAIR Title: Source: The Operationalisation of the Integrated Approach: Submission of STAIR to the Consultation of the Green Paper From Challenges to Opportunities: Towards a Common Strategic Framework
More informationAnnual Benefit-Risk Workshop
Annual Benefit-Risk Workshop Implementing an Internationally Acceptable Framework for the Benefit- Risk Assessment of Medicines: How close are we to this objective? 20-21 June 2013 PROGRAMME Venue: The
More informationReport OIE Animal Welfare Global Forum Supporting implementation of OIE Standards Paris, France, March 2018
Report OIE Animal Welfare Global Forum Supporting implementation of OIE Standards Paris, France, 28-29 March 2018 1. Background: In fulfilling its mandate to protect animal health and welfare, the OIE
More informationAn Essential Health and Biomedical R&D Treaty
An Essential Health and Biomedical R&D Treaty Submission by Health Action International Global, Initiative for Health & Equity in Society, Knowledge Ecology International, Médecins Sans Frontières, Third
More informationLife sciences road map pathway to a national strategy
Life sciences road map pathway to a national strategy Illustrations: Itziar Castany Ramirez Production: Ministry of Enterprise and Innovation Article no: N2018.34 Contents Introduction 4 Pathway to a national
More informationBayer Inc. Science for a Better Life. Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division
Bayer Inc. Science for a Better Life Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division Please review your career path to date, leading to your
More informationNHS Next Stage Review: Innovation
NHS Next Stage Review: Innovation January 2008 Introduction 1. The Academy of Medical Sciences welcomes the opportunity to contribute to the NHS Next Stage Review. In this short response we have focused
More informationElements of a global strategy and plan of action
INTERGOVERNMENTAL WORKING GROUP A/PHI/IGWG/1/5 ON PUBLIC HEALTH, INNOVATION AND 8 December 2006 INTELLECTUAL PROPERTY Agenda item 2.3 Elements of a global strategy and plan of action Progress to date in
More informationGary Condran Associate Director Bureau of Pharmaceutical Sciences, Therapeutic Product Directorate, HPFB, Health Canada
Gary Condran Associate Director Bureau of Pharmaceutical Sciences, Therapeutic Product Directorate, HPFB, Health Canada EDQM International Conference 19-20 September 2017 1 Concept History Mission Objectives
More informationSecurity and Risk Assessment in GDPR: from policy to implementation
Global Data Privacy Security and Risk Assessment in GDPR: from policy to implementation Enisa Workshop Roma - February 8, 2018 Nicola Orlandi Head of Data Privacy Pharma Nicola Orlandi Nicola Orlandi is
More informationLSIF Convenor s Summary Report to CTI
2016/SOM1/CTI/054 Agenda Item: 11 LSIF Convenor s Summary Report to CTI Purpose: Consideration Submitted by: LSIF PG Chair First Committee on Trade and Investment Meeting Lima, Peru 28-29 February 2016
More informationEMA-HTA workshop Bringing together stakeholders for early dialogue in medicines development
EMA-HTA workshop Bringing together stakeholders for early dialogue in medicines development Report from the public workshop hosted by the European Medicines Agency (EMA) in London on 26 November 2013 An
More informationTowards a Consumer-Driven Energy System
IEA Committee on Energy Research and Technology EXPERTS GROUP ON R&D PRIORITY-SETTING AND EVALUATION Towards a Consumer-Driven Energy System Understanding Human Behaviour Workshop Summary 12-13 October
More informationCreating a Vision for Health Literacy s Future: The Research Agenda
Creating a Vision for Health Literacy s Future: The Research Agenda The 8th Annual Health Literacy Research Conference Bethesda, Maryland October 14, 2016 1 Today s Agenda Introduction Michael Villaire
More informationNOTE Strategic Forum for International S&T Cooperation (SFIC) opinion on the ERA Framework (input to the ERAC opinion on the ERA Framework)
EUROPEAN UNION EUROPEAN RESEARCH AREA COMMITTEE Strategic Forum for International S&T Cooperation Secretariat Brussels, 21 November 2011 ERAC-SFIC 1356/11 NOTE Subject: Strategic Forum for International
More informationCentre for the Advancement of Health Innovations (CAHI)
Centre for the Advancement of Health Innovations (CAHI) Excellence in Clinical Innovation and Technology Evaluation Monday, April 16 th, 2012 The Old Mill Inn and Spa, Toronto ON Leslie Levin MB, MD, FRCP
More informationInteraction btw. the GDPR and Clinical Trials Regulation
Interaction btw. the GDPR and Clinical Trials Marjut Salokannel SaReCo Oslo, Clinical Trials (CTR) approved in 2014 and will most likely come into effect as of Oct. 2018 all information btw. the parties
More informationMedical Technology Association of NZ. Proposed European Union/New Zealand Free Trade Agreement. Submission to Ministry of Foreign Affairs & Trade
Medical Technology Association of NZ Proposed European Union/New Zealand Free Trade Agreement Submission to Ministry of Foreign Affairs & Trade February 2016 1 Introduction The Medical Technology Association
More information